CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- 4 Open-market sale EVP, Chief Technical Officer sold 2,028 shares at an average $37.65 ($76,357)
- 4 Open-market sale EVP, General Counsel sold 1,138 shares at $37.21 ($42,345)
- 8-K Event Results of operations · Regulation FD disclosure · Other events
- 4 Option exercise EVP, Chief Scientific Officer acquired 3,500 shares (option exercise)
- 4 Option exercise President and CEO acquired 7,848 shares (option exercise)
- 4 Option exercise EVP, Chief Medical Officer acquired 3,187 shares (option exercise)
- 4 Option exercise EVP, Chief Financial Officer acquired 3,062 shares (option exercise)
- 8-K Event Material agreement
- 424B5 Offering Prospectus
- 8-K Event Regulation FD disclosure · Other events
- 8-K Event Regulation FD disclosure · Other events
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Regulation FD disclosure · Other events
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Other events
- 4 Grant or award Director acquired 5,197 shares (grant or award)
- 4 Grant or award Director acquired 5,197 shares (grant or award)
- 4 Grant or award Director acquired 5,197 shares (grant or award)
Page 14 of 37 · 725 filings